title: [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
abstract: Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of choroidal and retinal neovascularization. Anti-VEGF therapy changed the standard-of-care for ocular disease with neovascularisation. This article presents one promising new drug--VEGF Trap-Eye--and results of clinical trials evaluating its efficacy in the treatment of wet age-related macular degeneration, central retinal vain occlusion, diabetic macular edema and choroidal neovascularization secondary to pathologic myopia.
authors: Klinika Okulistyki Ogólnej, Katedra Okulistyki Uniwersytetu Medycznego w Lublinie. robertrejdak@yahoo.com
authors: Robert
authors: R
authors: Rejdak
authors: Małgorzata
authors: M
authors: Szkaradek
authors: Wesam
authors: W
authors: Taslaq
authors: Jakub J
authors: JJ
authors: Kałuzny
authors: Pawel
authors: P
authors: Grieb
authors: Anselm G M
authors: AG
authors: Jünemann
mesh_terms: D020256:Choroidal Neovascularization / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008269:Macular Edema / Q000188:drug therapy*; D009216:Myopia / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012170:Retinal Vein Occlusion / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor